Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amneal Makes It Three With Pegfilgrastim Approval

Third US Biosimilar Fylnetra Follows FDA Nods For Filgrastim And Bevacizumab

Executive Summary

Amneal has celebrated its third US biosimilar approval of 2022 with an FDA nod for its Fylnetra (pegfilgrastim-pbbk) rival to Neulasta, as the firm makes launch preparations for all three products across the second half of the year.

You may also be interested in...



Amneal Completes Hat Trick With Delayed $2.6bn US Pegfilgrastim Entry

With its pure partnered approach, US-based player Amneal has tallied up its third biosimilar launch in the market.

Amneal Eyes Multiple Targets As It Seeks To Maintain Momentum

As Amneal reported first-quarter results, the firm’s management pointed to a number of specific product opportunities on the horizon as the company seeks to maintain growth momentum.

Amneal Says Vertical Integration Will Be Key To Compete In Biosimilars

Stressing the need for vertical integration to be a successful biosimilars developer in the long run, Amneal co-CEO Chirag Patel has set out the firm’s future strategy in the area – including aiming to be quicker to market with future launches – as Amneal proves itself against rival biosimilars players in the US market.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel